Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADSC-SVF-002 is an autologous cell therapy product consisting of a stromal vascular fraction (SVF) derived from a patient's own adipose tissue. The SVF is a heterogeneous population of cells, including adipose-derived stem cells (ADSCs), endothelial progenitor cells, pericytes, and various immune cells, which are isolated from subcutaneous fat harvested via liposuction. Developed by AdiSave, ADSC-SVF-002 is designed to be administered subcutaneously, either alone or in combination with autologous fat, to treat soft tissue defects and promote the healing of chronic or abnormal wounds. The therapeutic mechanism relies on the regenerative and angiogenic properties of the ADSCs and other cellular components within the fraction, which facilitate tissue repair through both direct differentiation and the secretion of trophic factors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ADSC-SVF-002.